Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

NCT01222195 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Low accrual.

Conditions

Leukemia

Interventions

DRUG: Lenalidomide
DRUG: Darbepoetin alfa

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]